Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Cipla
Moodys
Mallinckrodt
Baxter
Johnson and Johnson
Queensland Health
QuintilesIMS
UBS
Covington

Generated: October 17, 2017

DrugPatentWatch Database Preview

Telithromycin - Generic Drug Details

« Back to Dashboard

What are the generic sources for telithromycin and what is the scope of telithromycin freedom to operate?

Telithromycin
is the generic ingredient in one branded drug marketed by Sanofi Aventis Us and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Telithromycin has sixty-three patent family members in thirty-nine countries and six supplementary protection certificates in five countries.

One supplier is listed for this compound.

Summary for Generic Name: telithromycin

US Patents:1
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list41
Clinical Trials: see list27
Patent Applications: see list3,701
Therapeutic Class:Antibacterials
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:telithromycin at DailyMed

Pharmacology for Ingredient: telithromycin

Ingredient-typeKetolides
Drug ClassKetolide Antibacterial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us
KETEK
telithromycin
TABLET;ORAL021144-001Apr 1, 2004DISCNNoNo► Subscribe► SubscribeYY ► Subscribe
Sanofi Aventis Us
KETEK
telithromycin
TABLET;ORAL021144-002Feb 9, 2005DISCNNoNo► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: telithromycin

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us
KETEK
telithromycin
TABLET;ORAL021144-002Feb 9, 2005► Subscribe► Subscribe
Sanofi Aventis Us
KETEK
telithromycin
TABLET;ORAL021144-001Apr 1, 2004► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: telithromycin

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,100,404 Erythromycin compounds► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: telithromycin

Country Document Number Estimated Expiration
Romania113350► Subscribe
Algeria1878► Subscribe
Hungary9904687► Subscribe
Slovakia281707► Subscribe
Finland111263► Subscribe
Japan2007045847► Subscribe
JapanH11152296► Subscribe
Mexico9605208► Subscribe
Hungary219599► Subscribe
Slovakia140296► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: TELITHROMYCIN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2002001,C0680967Lithuania► SubscribePRODUCT NAME: TELITHROMYCINUM (11,12-DIDEOKSI 3-DE((2,6-DIDEOKSI-3-C-METIL-3-O-METIL-ALFA-L-RIBOHEKSOPIRANOZIL)OKSI) 6-O-METIL 3-OKSO 12,11-(OKSIKARBONIL ((4-(4-(3-PIRIDINIL) 1H-IMIDAZOL-1-IL)BUTIL)IMINO))ERITROMICINAS); REGISTRATION NO/DATE: 01/7551/9 20011107
2002001Lithuania► SubscribePRODUCT NAME: TELITHROMYCINUM (11,12-DIDEOKSI 3-DE((2,6-DIDEOKSI-3-C-METIL-3-O-METIL-ALFA-L-RIBOHEKSOPIRANOZIL)OKSI) 6-O-METIL 3-OKSO 12,11-(OKSIKARBONIL ((4-(4-(3-PIRIDINIL) 1H-IMIDAZOL-1-IL)BUTIL)IMINO))ERITROMICINAS); REGISTRATION NO/DATE: 01/7551/9 20011107
C0055France► SubscribePRODUCT NAME: TELITHROMYCINE; REGISTRATION NO/DATE: EU/1/01/191/001 20010709
2002 00001Denmark► SubscribeDKCTFF , , EXPIRES:
C/GB02/001United Kingdom► SubscribePRODUCT NAME: TELITHROMYCIN AND ADDITION SALTS THEREOF WITH PHARMACEUTICALLY ACCEPTABLE ACIDS; REGISTERED: UK EU/1/01/191/001-004 20010710
C030/2001Ireland► SubscribeSPC030/2001: 20031204, EXPIRES: 20160708
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
Covington
Johnson and Johnson
Merck
Harvard Business School
UBS
Colorcon
Fuji
Mallinckrodt
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot